Greenwich LifeSciences won UK regulatory approval to expand its FLAMINGO-01 oncology trial, broadening patient access and moving a key clinical program forward.

Greenwich LifeSciences won UK regulatory approval to expand its FLAMINGO-01 oncology trial, broadening patient access and moving a key clinical program forward. The decision follows earlier European clearance to use commercial GP2 in the study.